Aurobindo Pharma share news, announcements and annual reports

NSE: AUROPHARMABSE: 524804Pharmaceuticals & BiotechnologyMid Cap

Aurobindo Pharma Limited · Face value ₹1 · Listed Apr 1995 on BSE, Jul 2000 on NSE

₹1,644.80₹17.30 (1.06%)BSE ₹1,640.10

Share price at the NSE close on 28 Oct 2026. Previous close ₹1,627.50.

28 Oct: open ₹1,625.00, high ₹1,650.00, low ₹1,609.10

52-week range of traded prices to 28 Oct 2026

₹1,081.40Low, 28 Oct 2025₹1,740.00High, 24 Sep 2026

Next results date: the board meets on 4 Nov 2026 to consider: financial results and dividend. The notice · Results calendar

Market cap: ₹94,638 Cr138th largest listed
P/E: 25.49
P/B: 2.50
Dividend yield: Nonein the last 12 months
ROE: 10.5%
ROCE: 11.5%
Debt to equity: 0.20
Volume, NSE: 5,54,48548.5% delivered

Aurobindo Pharma board meetings

124 filed, newest first. Page 1 of 3.

Oct 2026
- 26 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2026 and dividend
Jul 2026
- 27 Jul · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2026
May 2026
- 12 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2026
Apr 2026
- 6 Apr · Board meeting
  Outcome of Board Meeting held on April 06, 2026.
Mar 2026
- 31 Mar · Board meeting
  To consider buyback for equity shares
Feb 2026
- 9 Feb · Board meeting
  Outcome of Board meeting held on February 09, 2026.
Jan 2026
- 30 Jan · Board meeting
  To consider and approve the financial results for the period ended December 31, 2025
Oct 2025
- 24 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2025
Jul 2025
- 23 Jul · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2025 and dividend
May 2025
- 16 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2025
Feb 2025
- 6 Feb · Board meeting
  Board meeting held on February 06, 2025.
Jan 2025
- 17 Jan · Board meeting
  To consider and approve the financial results for the period ended December 31, 2024
Nov 2024
- 9 Nov · Board meeting
  Board meeting held on November 09, 2024.
- 1 Nov · Board meeting
  To consider and approve the financial results for the period ended September 30, 2024
Aug 2024
- 10 Aug · Board meeting
  Board meeting held on August 10, 2024.
Jul 2024
- 31 Jul · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2024
- 18 Jul · Board meeting
  Board meeting held on July 18, 2024.
- 14 Jul · Board meeting
  To consider buyback for equity shares
May 2024
- 25 May · Board meeting
  Board meeting held on May 25, 2024.
- 16 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2024
Feb 2024
- 1 Feb · Board meeting
  To consider and approve the financial results for the period ended December 31, 2023
Nov 2023
- 9 Nov · Board meeting
  Board meeting held on November 09, 2023.
Oct 2023
- 27 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2023 and dividend
Aug 2023
- 3 Aug · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2023
May 2023
- 27 May · Board meeting
  Board meeting held on May 27, 2023.
- 18 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2023
Feb 2023
- 9 Feb · Board meeting
  Board meeting held on February 09, 2023.
Jan 2023
- 31 Jan · Board meeting
  We hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, February 9, 2023 to consider and approve inter alia, the following:1. Standalone & Consolidated Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022 and2. Payment of Interim Dividend, if any, for the financial year 2022-23.Further to our letter dated December 29, 2022 informing about the closure of Trading Window of the Company from January 1, 2023 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the third quarter and nine months period ended December 31, 2022, we inform you that the Trading Window will remain closed up to February 11, 2023 and shall be re-opened on February 12, 2023.
Oct 2022
- 31 Oct · Board meeting
  We hereby inform that a Meeting of the Board of Directors of the Company will be held on Saturday, November 12, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022.Further to our letter dated September 28, 2022 informing the closure of Trading Window of the Company from October 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the second quarter and half year ended September 30, 2022, we inform you that the Trading Window will remain closed up to November 14, 2022 and shall be re-opened on November 15, 2022.
Aug 2022
- 11 Aug · Board meeting
  Board Meeting held on 11-Aug-2022 to consider financial statements for the period ended June 2022 and Other business matters
- 3 Aug · Board meeting
  We hereby inform that a Meeting of the Board of Directors of the Company will be held on Thursday, August 11, 2022 to consider and approve inter alia, the Standalone & Consolidated Unaudited Financial Results of the Company for the first quarter ended June 30, 2022.Further to our letter dated June 28, 2022 informing the closure of Trading Window of the Company from July 1, 2022 until 48 hours from the date of declaration of the Unaudited Financial Results of the Company for the first quarter ended June 30, 2022, we inform you that the Trading Window will remain closed up to August 13, 2022 and shall be re-opened on August 14, 2022.
May 2022
- 30 May · Board meeting
  Board Meeting held on 30-May-2022 to consider financial statements for the period ended March 2022 and Dividend
- 20 May · Board meeting
  We hereby inform pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, that a Meeting of the Board of Directors of the Company will be held on Monday, May 30, 2022 to consider and approve inter alia, the following:1. Standalone & Consolidated Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022 and2. Payment of Fourth Interim Dividend, if any, for the financial year 2021-22. Please note that the record date for the purpose of determining the entitlement of the equity shareholders for the aforesaid interim dividend, if declared, is fixed as Friday, June 3, 2022.Further to our letter dated March 29, 2022 informing the closure of Trading Window of the Company from April 1, 2022 until 48 hours from the date of declaration of the Audited Financial Results of the Company for the fourth quarter and year ended March 31, 2022, we inform you that the Trading Window will remain closed up to June 1, 2022 and shall be re-opened on June 2, 2022.
Feb 2022
- 9 Feb · Board meeting
  Board meeting held on February 09, 2022.
Jan 2022
- 31 Jan · Board meeting
  To consider and approve the financial results for the period ended December 31, 2021 and dividend
Nov 2021
- 8 Nov · Board meeting
  Board meeting held on November 08, 2021.
Oct 2021
- 30 Oct · Board meeting
  To consider and approve the financial results for the period ended September 30, 2021 and dividend
Aug 2021
- 12 Aug · Board meeting
  Board meeting held on August 12, 2021.
- 4 Aug · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2021 and dividend
May 2021
- 31 May · Board meeting
  Board meeting held on May 31, 2021.
- 24 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2021
Feb 2021
- 10 Feb · Board meeting
  Board meeting held on February 10, 2021.
- 1 Feb · Board meeting
  To consider and approve the financial results for the period ended December 31, 2020 and dividend
Nov 2020
- 11 Nov · Board meeting
  Outcome of Board Meeting held on November 11, 2020.The Board of Directors of the Company at its meeting held today, November 11, 2020, has, inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company for the Second Quarter and half year ended September 30, 2020 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.2. a Second Interim Dividend @ 125% i.e Rs.1.25 (Rupee one and paise twenty five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2020-21. The Company has fixed November 24, 2020 as the Record Date for the purpose of payment of Second Interim Dividend and the same will be paid on or before December 4, 2020.3. the transfer of business undertaking of Auronext Pharma Private Limited, a wholly owned subsidiary of the Company, on a going concern basis, to Eugia Pharma Specialities Limited, another wholly owned step-down subsidiary of the Company, through execution of a business transfer agreement. Additional Disclosures as required under SEBI Circular No. ClR/CFD/CMD/4/2015 dated September 9, 2015, are provided at Annexure-"A".
- 2 Nov · Board meeting
  To consider and approve the financial results for the period ended September 30, 2020 and dividend
Aug 2020
- 12 Aug · Board meeting
  Outcome of Board Meeting held on August 12, 2020.
- 5 Aug · Board meeting
  To consider and approve the financial results for the period ended Jun 30, 2020 and dividend
Jun 2020
- 3 Jun · Board meeting
  Board meeting held on Jun 03, 2020.
May 2020
- 27 May · Board meeting
  To consider and approve the financial results for the period ended March 31, 2020
Feb 2020
- 6 Feb · Board meeting
  Board meeting held on February 06, 2020.

Aurobindo Pharma board meetings

Oct 2026

Jul 2026

May 2026

Apr 2026

Mar 2026

Feb 2026

Jan 2026

Oct 2025

Jul 2025

May 2025

Feb 2025

Jan 2025

Nov 2024

Aug 2024

Jul 2024

May 2024

Feb 2024

Nov 2023

Oct 2023

Aug 2023

May 2023

Feb 2023

Jan 2023

Oct 2022

Aug 2022

May 2022

Feb 2022

Jan 2022

Nov 2021

Oct 2021

Aug 2021

May 2021

Feb 2021

Nov 2020

Aug 2020

Jun 2020

May 2020

Feb 2020